Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-Cell Lymphoma.

Next Previous
X
Search
Trial Profile

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-Cell Lymphoma.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms R2CHOP-1

    • Most Recent Events

    • 02 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 27 Nov 2012 Results will be presented at the 54th American Society of Hematology (ASH-2012) Annual Meeting according to a Celgene International media release.
    • 03 Jul 2012 Planned number of patients changed from 30 to 110 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top